Abstract
Clinical efficacy and safety of DL-8280, a new antimicrobial agent, studied in 19 patients with mainly respiratory tract infection.
The drug was administered at a daily dose of 200-400 mg orally for seven to 14 days.
Clinical responses were excellent in four cases, good in 14 cases and fair in one case, showing an efficacy rate of 94.7%.
Eradication of bacteria was noted in 13 of 14 strains (92.9%).
Rash was seen in one case.
